Apogee Therapeutics (APGE) Stock Price, News & Analysis

Company Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $50.93 to $52.23
• 50-Day Range: $45.25 to $59.92
• 52-Week Range: $14.19 to $72.29
• Volume: 198,032 shs
• Average Volume: 503,497 shs
• Market Capitalization: $3.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $78.50
• Consensus Rating: Buy

Apogee Therapeutics Stock Analysis - MarketRank™

Apogee Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 476th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Apogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Apogee Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Apogee Therapeutics is -24.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apogee Therapeutics is -24.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apogee Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.90% of the float of Apogee Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Apogee Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Apogee Therapeutics has recently decreased by 11.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apogee Therapeutics does not currently pay a dividend.

Dividend Growth

Apogee Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.90% of the float of Apogee Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Apogee Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Apogee Therapeutics has recently decreased by 11.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.90

News Sentiment

Apogee Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Apogee Therapeutics this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for APGE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,058,635.00 in company stock.

Percentage Held by Insiders

36.10% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APGE Stock Analysis - Frequently Asked Questions

How have APGE shares performed this year?

Apogee Therapeutics' stock was trading at $27.94 at the beginning of the year. Since then, APGE shares have increased by 84.1% and is now trading at $51.43.
View the best growth stocks for 2024 here.

How were Apogee Therapeutics' earnings last quarter?

Apogee Therapeutics, Inc. (NASDAQ:APGE) announced its earnings results on Monday, August, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.60).

When did Apogee Therapeutics IPO?

Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share.

Who are Apogee Therapeutics' major shareholders?

Top institutional investors of Apogee Therapeutics include Waypoint Capital Advisors LLC (1.07%), Handelsbanken Fonder AB (0.02%), SG Americas Securities LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski and Jane Henderson.
View institutional ownership trends.

How do I buy shares of Apogee Therapeutics?

Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Apogee Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 10/23/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APGE
• CUSIP: N/A
• CIK: 1974640
• Web: www.apogeetherapeutics.com
• Phone: 650-394-5230
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $78.50
• High Stock Price Target: $95.00
• Low Stock Price Target: $43.00
• Potential Upside/Downside: +52.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-83,990,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.05%
• Return on Assets: -19.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.70
• Quick Ratio: 27.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.50 per share
• Price / Book: 6.86

Miscellaneous

• Outstanding Shares: 58,456,000
• Free Float: 28,754,000
• Market Cap: $3.01 billion
• Optionable: Optionable
• Beta: 2.75